Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRS001
MIFTS: 52

Serous Cystadenocarcinoma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Serous Cystadenocarcinoma

About this section

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 12 15
Cystadenocarcinoma, Serous 43 71
Serous Adenocarcinoma 12 17
Cystadenocarcinoma Serous 54
Serous Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3114
MeSH 43 D018284
NCIt 49 C3778
SNOMED-CT 67 90725004
UMLS 71 C0206701
Sources

Summaries for Serous Cystadenocarcinoma

About this section
Disease Ontology : 12 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary : Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to endometrial serous adenocarcinoma and fallopian tube carcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Everolimus and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and pancreas, and related phenotypes are Increased cell death in HCT116 cells and cardiovascular system

Wikipedia : 74 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Sources

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 endometrial serous adenocarcinoma 34.4 TP53 PPP2R1A PIK3CA PGR FBXW7 ERBB2
2 fallopian tube carcinoma 33.0 VEGFA TP53 PGR MMP2 ERBB2
3 ovarian serous cystadenocarcinoma 32.6 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
4 ovarian cystadenocarcinoma 31.5 ZNF217 TP53 PIK3CA MUC16 HRAS ERBB2
5 peritoneal mesothelioma 31.1 VEGFA PGR MUC16
6 clear cell adenocarcinoma 31.1 TP53 PIK3CA MUC16
7 endometrioid ovary carcinoma 31.0 TP53 PPP2R1A PIK3CA
8 adenocarcinoma 31.0 VEGFA TP53 PIK3CA MMP2 HRAS ERBB2
9 papillary adenocarcinoma 31.0 TP53 PGR MUC16 HRAS ERBB2
10 adenofibroma 31.0 TP53 MUC16 BRAF
11 ovarian cyst 30.9 VEGFA MUC16 ESR2
12 cervical adenocarcinoma 30.9 TP53 PGR ERBB2 CDKN1A AKT1
13 endosalpingiosis 30.9 TP53 PGR HRAS
14 endometrial hyperplasia 30.9 VEGFA TP53 PGR ESR2
15 uterine corpus endometrial carcinoma 30.9 TP53 PPP2R1A PIK3CA HRAS
16 ovarian carcinosarcoma 30.9 TP53 PPP2R1A PIK3CA ERBB2
17 ovarian clear cell carcinoma 30.8 ZNF217 VEGFA TP53 PPP2R1A PIK3CA MUC16
18 mature teratoma 30.8 TP53 NANOG ERBB2 BRAF
19 carcinosarcoma 30.7 TP53 PPP2R1A PIK3CA PGR HRAS FBXW7
20 in situ carcinoma 30.7 TP53 PIK3CA PGR HRAS ERBB2 AKT1
21 endometrial adenocarcinoma 30.7 VEGFA TP53 PGR ESR2 ERBB2 AKT1
22 primary peritoneal carcinoma 30.6 VEGFA TP53 PGR MUC16 ERBB2
23 testicular germ cell tumor 30.6 TP53 MUC16 HRAS AKT1
24 endocervical adenocarcinoma 30.6 TP53 PIK3CA PGR ERBB2 CDKN1A
25 adenosquamous carcinoma 30.6 TP53 PIK3CA PGR
26 cervical squamous cell carcinoma 30.6 VEGFA TP53 PIK3CA MMP2 AKT1
27 tuberous sclerosis 30.5 VEGFA TP53 PIK3CA AKT1
28 apocrine adenocarcinoma 30.5 TP53 PGR ERBB2
29 bilateral breast cancer 30.5 PIK3CA PGR ERBB2
30 myoma 30.5 TP53 PGR MUC16
31 ovarian clear cell adenocarcinoma 30.5 TP53 PIK3CA PGR ESR2
32 adenomyosis 30.5 VEGFA TP53 PGR MMP2 ESR2
33 rectum adenocarcinoma 30.5 TP53 PIK3CA HRAS ERBB2
34 endocervical carcinoma 30.4 TP53 PIK3CA PGR ERBB2
35 lynch syndrome 30.4 TP53 PIK3CA HRAS ERBB2 BRAF
36 pancreatic ductal carcinoma 30.4 VEGFA TP53 MUC16 ERBB2
37 breast ductal carcinoma 30.3 VEGFA TP53 PGR ESR2 ERBB2 CDKN1A
38 li-fraumeni syndrome 30.3 TP53 HRAS ERBB2 CDKN1A
39 exanthem 30.3 VEGFA HRAS ERBB2 AKT1
40 endometriosis 30.3 VEGFA TP53 PGR MUC16 MMP2 ESR2
41 differentiated thyroid carcinoma 30.3 VEGFA TP53 NRAS HRAS BRAF
42 pelvic organ prolapse 30.3 TP53 PGR MMP2 ESR2
43 transitional cell carcinoma 30.3 TP53 PIK3CA HRAS ERBB2 CDKN1A BRAF
44 wilms tumor 1 30.2 VEGFA TP53 PGR HRAS FBXW7 ERBB2
45 peripheral nervous system disease 30.2 VEGFA TP53 ERBB2 B2M AKT1
46 rhabdomyosarcoma 30.2 VEGFA TP53 HRAS CDKN1A AKT1
47 mucinous adenocarcinoma 30.1 VEGFA TP53 PGR MUC16 ESR2 ERBB2
48 squamous cell papilloma 30.1 TP53 HRAS
49 ovary adenocarcinoma 30.1 VEGFA TP53 PPP2R1A PIK3CA PGR MUC16
50 sarcoma 30.1 VEGFA TP53 PIK3CA NRAS HRAS CDKN1A

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma
Sources

Symptoms & Phenotypes for Serous Cystadenocarcinoma

About this section

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in HCT116 cells GR00103-A-0 8.8 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
2 cellular MP:0005384 10.47 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
3 homeostasis/metabolism MP:0005376 10.47 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
4 endocrine/exocrine gland MP:0005379 10.44 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
5 growth/size/body region MP:0005378 10.43 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
6 behavior/neurological MP:0005386 10.42 AKT1 BRAF CDKN1A ERBB2 ESR2 HRAS
7 embryo MP:0005380 10.42 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
8 mortality/aging MP:0010768 10.41 AKT1 B2M BIRC5 BRAF CDKN1A ERBB2
9 immune system MP:0005387 10.37 AKT1 B2M BIRC5 BRAF CDKN1A ESR2
10 integument MP:0010771 10.36 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
11 hematopoietic system MP:0005397 10.33 AKT1 B2M BIRC5 BRAF CDKN1A ESR2
12 digestive/alimentary MP:0005381 10.32 B2M BRAF CDKN1A ERBB2 ESR2 FBXW7
13 neoplasm MP:0002006 10.31 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
14 craniofacial MP:0005382 10.24 BRAF CDKN1A ERBB2 FBXW7 HRAS MMP2
15 liver/biliary system MP:0005370 10.18 AKT1 B2M BRAF CDKN1A ESR2 FBXW7
16 nervous system MP:0003631 10.18 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
17 muscle MP:0005369 10.17 AKT1 BRAF CDKN1A ERBB2 ESR2 MMP2
18 limbs/digits/tail MP:0005371 10.1 BRAF CDKN1A ERBB2 ESR2 NRAS PGR
19 normal MP:0002873 10.07 AKT1 BIRC5 BRAF ERBB2 ESR2 FBXW7
20 no phenotypic analysis MP:0003012 9.97 CDKN1A ESR2 HRAS NANOG NRAS PGR
21 reproductive system MP:0005389 9.85 AKT1 B2M BRAF CDKN1A ERBB2 ESR2
22 respiratory system MP:0005388 9.7 AKT1 BRAF CDKN1A ERBB2 ESR2 FBXW7
23 skeleton MP:0005390 9.4 AKT1 BRAF CDKN1A ERBB2 ESR2 HRAS
Sources

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Epirubicin Approved Phase 3 56420-45-2 41867
5
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
6
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
7
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
8
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
9
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
10
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
11
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
13
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
14
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
15
Pembrolizumab Approved Phase 3 1374853-91-4
16
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
17
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
18
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
21
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
23
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
24
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
25 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
26
Liposomal doxorubicin Phase 3 31703
27 Anti-Bacterial Agents Phase 3
28 Antibiotics, Antitubercular Phase 3
29 Adjuvants, Immunologic Phase 3
30 Carotenoids Phase 3
31 Estrogen Antagonists Phase 2, Phase 3
32 Estrogen Receptor Antagonists Phase 2, Phase 3
33 Aromatase Inhibitors Phase 2, Phase 3
34 topoisomerase I inhibitors Phase 2, Phase 3
35 Anti-Infective Agents Phase 3
36 Hypoglycemic Agents Phase 2, Phase 3
37 Antioxidants Phase 2, Phase 3
38 Citrate Phase 2, Phase 3
39 Protective Agents Phase 2, Phase 3
40 Antiviral Agents Phase 3
41 taxane Phase 3
42 Mitogens Phase 2, Phase 3
43 Angiogenesis Inhibitors Phase 2, Phase 3
44 Antineoplastic Agents, Immunological Phase 3
45 Immunoglobulins Phase 2, Phase 3
46 Antibodies Phase 2, Phase 3
47 Endothelial Growth Factors Phase 2, Phase 3
48 Immunoglobulins, Intravenous Phase 2, Phase 3
49 Antibodies, Monoclonal Phase 2, Phase 3
50 Immunoglobulin G Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
2 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
4 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
5 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
7 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
8 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
9 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
10 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
12 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
13 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
14 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
16 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
17 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
18 Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery Recruiting NCT04063527 Phase 3 adjuvant chemotherapy
19 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
20 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
21 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
22 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
23 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
24 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
25 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
26 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
27 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
28 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
29 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Suspended NCT03914612 Phase 3 Carboplatin;Paclitaxel
30 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
31 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
32 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
33 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
34 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
36 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
37 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
38 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
39 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
40 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
41 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
42 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
43 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
44 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
45 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
46 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
47 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
48 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
49 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
50 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxaneâ„¢) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Sources

Genetic Tests for Serous Cystadenocarcinoma

About this section
Sources

Anatomical Context for Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

40
Ovary, Breast, Pancreas, Lymph Node, Cervix, Liver, Uterus
Sources

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 1122)
# Title Authors PMID Year
1
Dipeptidyl peptidase IV in tumor progression. 54 61
16054016 2005
2
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. 54 61
12019149 2002
3
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. 54 61
11063654 2000
4
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 61 54
9852392 1999
5
Solitary splenic metastasis of an adenocarcinoma of the ovaries. 61 54
8938479 1996
6
Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. 61 54
8669868 1995
7
The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. 61 54
8494699 1993
8
Serum and tissue measurements of CA72-4 in ovarian cancer patients. 54 61
8381375 1993
9
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 54 61
1506732 1992
10
Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. 61
32565967 2020
11
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. 61
32356124 2020
12
Sunitinib as Successful Maintenance Therapy for Recurrent Pancreatic Serous Cystadenocarcinoma. 61
32541193 2020
13
Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. 61
32533167 2020
14
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. 61
32382997 2020
15
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020
16
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
17
Serous Microcystic Cystadenocarcinoma of the Pancreas with Synchronous Liver Metastases: Clinical Characteristics and Management. 61
32431986 2020
18
A common variant rs2272804 in the 5'UTR of RIBC2 inhibits downstream gene expression by creating an upstream open reading frame. 61
32329860 2020
19
Synchronous Cervical Adenocarcinoma and Ovarian Serous Adenocarcinoma-A Case Report and Literature Review. 61
32235322 2020
20
The androgen receptor expression and association with patient's survival in different cancers. 61
31759122 2020
21
Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. 61
32105524 2020
22
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. 61
32190072 2020
23
Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells. 61
31723239 2020
24
OTUD4: A Potential Prognosis Biomarker for Multiple Human Cancers. 61
32184655 2020
25
Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer. 61
32478062 2020
26
Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence. 61
32195366 2020
27
Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma. 61
32536817 2020
28
ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy. 61
31478407 2020
29
Identification of hub genes and key pathways associated with the progression of gynecological cancer. 61
31788113 2019
30
Ovarian Cancer Presenting as Cryptogenic Stroke from Patent Foramen Ovale. 61
31324738 2019
31
A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients. 61
31533939 2019
32
Interpretable deep neural network for cancer survival analysis by integrating genomic and clinical data. 61
31865908 2019
33
Surveillance and management for serous cystic neoplasms of the pancreas based on total hazards-a multi-center retrospective study from China. 61
32042823 2019
34
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. 61
31766991 2019
35
The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance. 61
31725636 2019
36
A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers. 61
31646556 2019
37
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2019
38
Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer. 61
31351675 2019
39
An Unlikely Route: Metastatic Ovarian Malignancy within the Duodenum. 61
31768358 2019
40
Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3. 61
31579405 2019
41
Fallopian tube serous adenocarcinoma with dizziness as the initial symptom: a case report. 61
31500488 2019
42
Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. 61
31491988 2019
43
Difficult Diagnosis of Peritoneal Serous Papillary Carcinoma in a 63-year-old Woman: A Case Report. 61
31448396 2019
44
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. 61
31076855 2019
45
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer. 61
31399054 2019
46
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 61
31029905 2019
47
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. 61
31406154 2019
48
Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. 61
31161471 2019
49
Serous Adenocarcinoma of Fallopian Tubes: Histological and Immunohistochemical Aspects. 61
30971070 2019
50
Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer. 61
31203199 2019
Sources

Variations for Serous Cystadenocarcinoma

About this section
Sources

Expression for Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Serous Cystadenocarcinoma.
Sources

Pathways for Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.31 YAP1 VEGFA TP53 PPP2R1A PIK3CA PGR
2
Innate Immune System 65
Show member pathways
 14.08 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
3
ERK Signaling 63
Show member pathways
 13.95 VEGFA TP53 PPP2R1A NRAS HRAS ESR2
4
Gene Expression 65
Show member pathways
 13.93 YAP1 VEGFA TP53 PPP2R1A PGR ESR2
5
HIV Life Cycle 65
Show member pathways
 13.86 PPP2R1A PIK3CA NRAS MUC16 HRAS FBXW7
6
GPCR Pathway 63
Show member pathways
 13.83 VEGFA TP53 PPP2R1A NRAS MMP2 HRAS
7
TGF-Beta Pathway 63
Show member pathways
 13.69 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
8
Developmental Biology 65
Show member pathways
 13.65 VEGFA PPP2R1A PIK3CA NRAS NANOG MMP2
9
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.6 TP53 PPP2R1A PIK3CA NRAS HRAS FBXW7
10
Akt Signaling 63
Show member pathways
 13.54 YAP1 TP53 PPP2R1A NRAS HRAS ERBB2
11
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.43 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
12
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.42 YAP1 VEGFA PPP2R1A NRAS NANOG HRAS
13
TNFR1 Pathway 63
Show member pathways
 13.23 VEGFA TP53 PIK3CA NRAS HRAS CDKN1A
14
GAB1 signalosome 65
Show member pathways
 13.22 TP53 PPP2R1A PIK3CA ERBB2 CDKN1A AKT1
15
Cytokine Signaling in Immune system 65
Show member pathways
 13.21 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
16
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.2 TP53 PPP2R1A PIK3CA NRAS HRAS CDKN1A
17
fMLP Pathway 63
Show member pathways
 13.12 VEGFA TP53 NRAS HRAS BRAF AKT1
18
PI3K-Akt signaling pathway 36
Show member pathways
 13.12 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
19
Human cytomegalovirus infection 36
Show member pathways
 13.09 VEGFA TP53 PIK3CA NRAS HRAS CDKN1A
20
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.06 VEGFA PIK3CA NRAS HRAS ERBB2 BRAF
21
Focal Adhesion 36 1
Show member pathways
 13.06 VEGFA PIK3CA NRAS HRAS ERBB2 BRAF
22
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13 PIK3CA NRAS HRAS ERBB2 BRAF AKT1
23
Endometrial cancer 36
Show member pathways
 12.96 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
24
Development Angiotensin activation of ERK 22
Show member pathways
 12.95 PIK3CA NRAS HRAS BRAF AKT1
25
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.93 PIK3CA HRAS CDKN1A BRAF BIRC5 AKT1
26
MAPK signaling pathway 36 1
12.93 VEGFA TP53 NRAS HRAS ERBB2 BRAF
27
Measles 36
Show member pathways
 12.92 TP53 PIK3CA CDKN1A B2M AKT1
28
Beta-Adrenergic Signaling 63
Show member pathways
 12.91 PPP2R1A NRAS HRAS BRAF AKT1
29
Ras signaling pathway 36
Show member pathways
 12.89 VEGFA PIK3CA NRAS HRAS BRAF AKT1
30
Circadian entrainment 36
Show member pathways
 12.88 PPP2R1A PIK3CA NRAS HRAS AKT1
31
Development HGF signaling pathway 22
Show member pathways
 12.88 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
32
Apoptosis Modulation and Signaling 1
Show member pathways
 12.87 TP53 PIK3CA NRAS HRAS CDKN1A BIRC5
33
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.87 TP53 PPP2R1A PIK3CA NRAS HRAS ERBB2
34
4-1BB Pathway 63
Show member pathways
 12.83 TP53 PPP2R1A NRAS HRAS BRAF AKT1
35
Relaxin signaling pathway 36
Show member pathways
 12.81 VEGFA PIK3CA PGR NRAS MMP2 HRAS
36
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.77 PIK3CA NRAS MMP2 HRAS AKT1
37
Gastric cancer 36
Show member pathways
 12.77 TP53 PIK3CA PGR NRAS HRAS ESR2
38
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.72 VEGFA PIK3CA NRAS HRAS AKT1
39
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.7 PPP2R1A PIK3CA NRAS HRAS BRAF
40
MicroRNAs in cancer 36
12.7 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
41
ErbB signaling pathway 36 1
Show member pathways
 12.7 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
42
VEGF Signaling 66
Show member pathways
 12.67 VEGFA TP53 PIK3CA NRAS HRAS AKT1
43
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.66 TP53 PPP2R1A PIK3CA HRAS CDKN1A AKT1
44
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.66 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
45
Glioma 36
Show member pathways
 12.66 TP53 PIK3CA NRAS MMP2 HRAS ESR2
46
Prolactin Signaling Pathway 36 1
Show member pathways
 12.65 PIK3CA NRAS HRAS ESR2 ERBB2 AKT1
47
Apoptosis Pathway 70
Show member pathways
 12.62 TP53 PIK3CA NRAS HRAS ERBB2 AKT1
48
JAK-STAT signaling pathway 36
Show member pathways
 12.59 PIK3CA NRAS HRAS CDKN1A AKT1
49
Development IGF-1 receptor signaling 22
Show member pathways
 12.57 TP53 PIK3CA HRAS CDKN1A BIRC5 AKT1
50
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.56 PIK3CA NRAS HRAS BRAF AKT1
Sources

GO Terms for Serous Cystadenocarcinoma

About this section

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 ZNF217 YAP1 TP53 PGR NANOG HRAS
2 cytosol GO:0005829 9.97 YAP1 TP53 PPP2R1A PIK3CA PGR HRAS
3 nucleus GO:0005634 9.83 ZNF217 YAP1 TP53 PPP2R1A PGR NANOG
4 mitochondrion GO:0005739 9.28 ZNF217 TP53 PPP2R1A PGR MMP2 FBXW7

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 YAP1 VEGFA TP53 PGR NANOG HRAS
2 positive regulation of cell proliferation GO:0008284 9.97 YAP1 VEGFA HRAS ERBB2 BIRC5 AKT1
3 negative regulation of apoptotic process GO:0043066 9.93 VEGFA TP53 CDKN1A BRAF BIRC5 AKT1
4 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA HRAS ERBB2 AKT1
5 transcription initiation from RNA polymerase II promoter GO:0006367 9.86 YAP1 PGR ESR2 CDKN1A
6 negative regulation of neuron apoptotic process GO:0043524 9.83 PIK3CA HRAS BRAF BIRC5
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.8 VEGFA BIRC5 AKT1
8 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA NRAS AKT1
9 positive regulation of gene expression GO:0010628 9.8 YAP1 VEGFA TP53 HRAS ERBB2 BRAF
10 negative regulation of cell growth GO:0030308 9.78 TP53 PPP2R1A ESR2 CDKN1A
11 vasculogenesis GO:0001570 9.77 YAP1 VEGFA FBXW7
12 somatic stem cell population maintenance GO:0035019 9.77 YAP1 NANOG BRAF
13 positive regulation of MAP kinase activity GO:0043406 9.76 VEGFA HRAS ERBB2
14 epidermal growth factor receptor signaling pathway GO:0007173 9.72 PIK3CA BRAF AKT1
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 VEGFA PIK3CA BRAF AKT1
16 phosphatidylinositol 3-kinase signaling GO:0014065 9.69 PIK3CA ERBB2 AKT1
17 Ras protein signal transduction GO:0007265 9.67 TP53 NRAS HRAS CDKN1A
18 positive regulation of organ growth GO:0046622 9.64 YAP1 AKT1
19 anoikis GO:0043276 9.63 PIK3CA AKT1
20 positive regulation of epithelial cell proliferation GO:0050679 9.62 YAP1 VEGFA HRAS ERBB2
21 regulation of cell cycle G1/S phase transition GO:1902806 9.61 FBXW7 CDKN1A
22 progesterone receptor signaling pathway GO:0050847 9.61 YAP1 PGR
23 intrinsic apoptotic signaling pathway GO:0097193 9.61 TP53 HRAS CDKN1A
24 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.57 VEGFA TP53
25 negative regulation of gene expression GO:0010629 9.56 YAP1 VEGFA TP53 PGR HRAS FBXW7
26 signal transduction by p53 class mediator GO:0072331 9.54 TP53 CDKN1A
27 cellular response to gamma radiation GO:0071480 9.46 YAP1 TP53 HRAS CDKN1A
28 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA TP53 PIK3CA NANOG MMP2 CDKN1A

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
2 enzyme binding GO:0019899 9.65 TP53 PGR ESR2 BIRC5 AKT1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.63 ZNF217 YAP1 TP53 PGR NANOG ESR2
4 transcription regulatory region DNA binding GO:0044212 9.62 ZNF217 YAP1 TP53 NANOG
5 identical protein binding GO:0042802 9.32 VEGFA TP53 PGR FBXW7 ESR2 ERBB2
Sources

Sources for Serous Cystadenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....